Wellington Partners
Edit

Wellington Partners

https://www.wellington-partners.com
Last activity: 08.08.2025
Active
Invests in categories: TechnologyMedTechDataHealthTechPlatformProductITServiceAppMusic
Wellington Partners is one of the most successful pan-European venture capital firms. With funds totalling over € 800 million, we have invested throughout Europe in companies that have the potential to become real market leaders for more than 15 years.

We are committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically lead financing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, our own commitment can go as high as € 15 million.

Providing funding is only one part of our business. After funding, the entrepreneurs we back have access to the advice and guidance of our complete team and our entire global network. Our investment professionals operate out of four offices, located in London, Munich, Zurich and Palo Alto. The pan-European and transatlantic makeup of our organisation enables us to support our portfolio in expanding globally.

To date, Wellington Partners has invested in more than 100 companies throughout Europe. We have been a part of great successes as well as dismal failures. In our view, success has always been the result of a great idea executed by a great team with strong leadership and commitment; plus an enormous amount of hard work and an ounce of luck, the good fortune to be in the right place at right time.
Likes
1.33K
Portfolio
92
Persons
8
Mentions
140
Location: Germany, Bavaria, Munich
Employees: 11-50
Founded date: 1998
Investment Type: Venture Capital
Investment Stage: Series A; Series C

Portfolio 92

DateNameWebsiteTotal RaisedLocation
08.08.2025SNIPR BIOM...sniprbiome.com$90.93MDenmark
11.07.2025NUCLIDIUM ...nuclidium.com$101.75MSwitzerlan...
16.03.2023Seamless T...seamlesstx.com$12.5MGermany, S...
25.02.2021Creative B...creativeballoons.de$18.25MGermany, B...
28.01.2021SIRS Thera...sirs-therapeutics.com--
09.01.2021ONWARDonwd.com$266.8MNetherland...
22.12.2020Minervax A...minervax.com$196.51MDenmark, C...
28.10.2020Sidekick H...sidekickhealth.com$76.5MSweden, Go...
07.05.2019Confo Ther...confotherapeutics.com$106.07MBelgium
26.11.2018Adrenomed ...adrenomed.com$55.23MGermany, B...
Show more

Persons 8

DateFirst NameLast NameTitleLinkedInLocation
-OlenaIonkinaFinance Ma...-
-Dr.Johannes F...Partnerlinkedin.c...-
-Dr.Varun Gupt...Partnerlinkedin.c...-
-KaiWohlberedtAssociatelinkedin.c...-
-HélèneVERGERExecutive ...linkedin.c...-
-ErichSchlickGeneral Pa...linkedin.c...-
-Dr.Robert Bus...Analystlinkedin.c...-
-FrankBoehnkeGeneral Pa...linkedin.c...-

Mentions in press and media 140

DateTitleDescription
08.08.2025SNIPR BIOME Secures €35 Million to Revolutionize CRISPR-MedicineCopenhagen's SNIPR BIOME clinched €35 million in Series B funding. This significant capital injection drives microbial CRISPR-medicine innovation. Funds target critical health challenges: developing CRISPR-Cas therapy for severe airway infe...
08.08.2025Danish BioTech scale-up SNIPR Biome raises €35 million to target antimicrobial resistance in diseases like cancerCopenhagen-based SNIPR Biome, a BioTech company innovating the development of microbial CRISPR-medicine, announced the close of a €35 million Series B raise to advance CRISPR-based therapies for cystic fibrosis airway infections, combat ant...
07.08.2025SNIPR BIOME Raises EUR 35M in Series B FundingSNIPR BIOME, a Copenhagen, Denmark-based company improving the development of microbial CRISPR-medicine, raised EUR 35M in Series B funding. Backers included Cystic Fibrosis Foundation and the German Federal Agency for Breakthrough Innovati...
12.07.2025Swiss Biotech Secures Major Funding for Advanced Cancer TreatmentsSwiss biotech firm NUCLIDIUM secured €84 million in Series B funding. This significant capital injection propels its proprietary copper-based theranostic platform. The company targets advanced cancer diagnosis and treatment. Funds will acce...
11.07.2025NUCLIDIUM raises €84M Series B to advance copper-based cancer therapiesNUCLIDIUM, a Swiss clinical-stage biotechnology company pioneering the development of next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer, has raised €84 million Series B funding. Leveraging copper is...
10.07.2025Swiss BioTech platform NUCLIDIUM raises €84 million for the diagnosis and treatment of cancerBasel-based NUCLIDIUM, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced the successful closing of its Series B financing round, raising €84 million. The round was led b...
10.07.2025CHF 79 million to advance Nuclidium’s copper-based radiopharmaceutical platform NUCLIDIUM’s differentiated platform links tumor-targeting molecules with copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics – to address current limitations in radiotheranostics, such as suboptimal clinical efficacy...
10.07.2025Nuclidium Raises €84M in Series B FundingNuclidium, a Basel, Switzerland-based clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, raised €84M in Series B funding The round was co-led by Angelini Ventures, Kurma Growth Opportuniti...
08.07.2025Aktiia’s Hilo Band Is First FDA-Cleared Cuffless BP Monitor for OTC Use Trusted by over 130,000 users globally, the Hilo Band has demonstrated the impact of Aktiia’s technology in real-world settings. With this FDA clearance, consumers in the U.S. will soon have access to the same clinically validated innovati...
26.06.2025+++ CarOnSale +++ Ostwestfalen-Lippe +++ Autodoc +++ Bürokratie +++ Bird +++ Rolf Christof Dienst +++Was gibt’s Neues? In unserem #StartupTicker liefern wir eine kompakte Übersicht über die wichtigsten Startup-Nachrichten des Tages (Donnerstag, 26. Juni). #STARTUPLAND SAVE THE DATE: Am 5. November findet unsere zweite STARTUPLAND statt. Es...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In